Kawasaki Disease - Diagnosis, IVIG, and Aspirin

Key Points

• Persistent fever with compatible mucocutaneous findings should prompt evaluation for Kawasaki disease.
• Infants can have incomplete disease with few classic signs but substantial coronary risk.
• IVIG 2 g/kg is the foundation of acute therapy.
• Aspirin is used acutely and then at antiplatelet dose until coronary risk is defined.
• A normal early echocardiogram does not exclude Kawasaki disease.
• Persistent fever after IVIG suggests resistant disease and requires active retreatment planning.
• Large coronary aneurysms may require systemic anticoagulation in addition to aspirin.

Algorithm

1. Document fever duration and current or resolved conjunctival, oral, rash, extremity, and lymph-node findings.
2. Obtain inflammatory markers and supportive laboratory studies; evaluate incomplete disease when fever is unexplained.
3. Obtain echocardiography with coronary z scores and cardiac-function assessment.
4. Give IVIG and aspirin promptly when diagnostic criteria are met or incomplete disease is sufficiently supported.
5. Assess IVIG-resistance and coronary-risk features and add corticosteroid or other therapy when indicated.
6. Reassess fever after IVIG and retreat resistant disease with cardiology or rheumatology guidance.
7. Repeat echocardiography on the recommended schedule and intensify antithrombotic therapy according to aneurysm size.
8. Provide long-term cardiology follow-up when any coronary abnormality persists.

Clinical Synopsis & Reasoning

Kawasaki disease is a medium-vessel vasculitis that predominantly affects children younger than 5 years. The classic presentation is at least five days of fever plus a combination of bilateral nonexudative conjunctival injection, oral mucosal changes, polymorphous rash, peripheral-extremity changes, and cervical lymphadenopathy. Experienced clinicians may diagnose and treat earlier when the clinical pattern is compelling, particularly if coronary abnormalities are already present. The findings are often sequential, so asking caregivers about symptoms that have already resolved is important. Perineal desquamation can occur early, while periungual peeling is usually later.

Incomplete Kawasaki disease is especially important in infants, who may have prolonged unexplained fever with fewer classic findings but a high risk of coronary disease. Use inflammatory markers and supportive laboratory features such as anemia for age, thrombocytosis after the first week, hypoalbuminemia, elevated alanine aminotransferase, sterile pyuria, and leukocytosis to guide evaluation. Echocardiography assesses coronary dimensions and cardiac function but a normal early study does not exclude Kawasaki disease. Coronary arteries are indexed to body surface area using z scores. Myocarditis, pericardial effusion, valvular regurgitation, and ventricular dysfunction can also occur.

The differential includes adenovirus, scarlet fever, toxic shock syndrome, measles, drug reactions, systemic juvenile idiopathic arthritis, and MIS-C. Exudative conjunctivitis, exudative pharyngitis, discrete oral ulcers, and generalized lymphadenopathy point more strongly toward alternatives. MIS-C often occurs after SARS-CoV-2 infection and more commonly produces prominent gastrointestinal symptoms, shock, myocardial dysfunction, lymphopenia, and thrombocytopenia rather than the later thrombocytosis typical of Kawasaki disease. The distinction can overlap, so treatment may require pediatric infectious disease, rheumatology, and cardiology input.

Treatment Strategy & Disposition

Give IVIG 2 g/kg as a single infusion to children with acute Kawasaki disease, ideally within the first 10 days of illness but later if ongoing inflammation or coronary abnormalities persist. Aspirin is given during the acute inflammatory phase. The 2024 AHA update notes that low- or medium-dose aspirin appears comparable to historical high-dose regimens for coronary outcomes; institutional protocols vary. Once the child is afebrile, transition to low-dose antiplatelet aspirin, generally continued until follow-up confirms no coronary involvement, and longer when aneurysms persist.

Assess risk for IVIG resistance and coronary aneurysm. High-risk children may benefit from adjunctive corticosteroids or other anti-inflammatory therapy such as infliximab as part of the initial or rescue strategy. A child with persistent or recrudescent fever at least 36 hours after IVIG completion requires reassessment for IVIG-resistant disease, infection, and other diagnoses. Management options include a second IVIG dose, corticosteroid, infliximab, or other immunomodulation depending on risk and specialist guidance.

Coronary aneurysm size determines thrombosis prevention. Low-dose aspirin may be sufficient for small abnormalities, while large or giant aneurysms can require aspirin plus systemic anticoagulation such as low-molecular-weight heparin or warfarin. Echocardiography should be obtained at diagnosis and repeated at guideline-based intervals, with more intensive imaging for evolving aneurysms. Admit during acute treatment and monitor for infusion reactions, myocarditis, arrhythmia, shock, and heart failure. Avoid live vaccines for the recommended interval after IVIG because passive antibodies can reduce vaccine effectiveness, while ensuring the child remains protected from influenza when long-term aspirin is used because of Reye syndrome concerns.

Epidemiology / Risk Factors

• Kawasaki disease is most common in children younger than 5 years.
• Incidence is substantially higher in East Asian populations, though disease occurs worldwide.
• It is a leading cause of acquired heart disease in children in many high-income countries.
• Coronary aneurysm risk falls markedly with timely IVIG therapy.

Investigations

Classic Clinical Features

Pharmacology

Prognosis / Complications

• Most treated children recover without permanent coronary damage.
• Giant coronary aneurysms carry long-term risks of thrombosis, stenosis, myocardial infarction, and need for lifelong surveillance.
• IVIG-resistant fever and very young age are associated with greater coronary risk.
• Myocardial dysfunction during the acute phase often improves, but severe shock requires intensive care.

Patient Education / Counseling

• Explain that the main reason for treatment and follow-up is protection of the coronary arteries even after fever resolves.
• Give clear instructions about aspirin dose and bleeding precautions.
• Seek urgent care for chest pain, unexplained dyspnea, syncope, or recurrent prolonged fever after treatment.
• Review live-vaccine timing after IVIG with the child's pediatrician.
• Families of children with persistent aneurysms should understand the need for long-term cardiology care and antithrombotic adherence.

Notes

Kawasaki disease is a longitudinal diagnosis. The fever, mucosal findings, platelet response, and coronary imaging evolve over time, so a child can look incomplete on the first day of evaluation and still have true disease. The clinical record should therefore capture historical findings, not just what is visible during one examination.

The 2024 AHA update also reinforces risk-stratified therapy. IVIG remains universal initial treatment, while adjunctive anti-inflammatory treatment is targeted more aggressively to children likely to resist IVIG or develop coronary disease. Long-term management is driven by the worst coronary involvement observed, even if aneurysms later regress, because vascular risk does not always return completely to baseline.

References

1. American Heart Association: 2024 Update on Diagnosis and Management of Kawasaki Disease — Link
2. American Heart Association: Top Things to Know, Kawasaki Disease 2024 — Link